LONDON and NEW YORK, May 20,
2015 /PRNewswire/ --
China, with 100 million
diabetics has already outpaced other nations in terms of number of
diabetics. Further, the market is estimated to grow many times as a
large proportion of the population is pre-diabetic who may become
diabetic in the near future. The China Diabetes Management Devices
market comprises continuous glucose monitors (CGM), SMBG
(self-monitoring blood glucose meters), manual insulin delivery
products, glucose test strips, lancets, syringes, insulin pens and
insulin pumps.
(Logo:
http://photos.prnewswire.com/prnh/20140502/685460 )
http://www.abmrg.com/China-Diabetes-Management-Devices---Market-Trends-Forecast-and-competitive-Landscape-2007---2020.html
Growth of the diabetes market in China is driven by high prevalence of diabetes
among the aging population, increased life expectancy, a surge in
sedentary life style, unhealthy diet, high stress levels and
increased disposable income. Also, to a large extent the market in
terms of volume is boosted by low priced local products which make
treatment affordable besides supporting adoption of new technology
products such as insulin pump and CGM in hospital segment and
insulin delivery products as well SMBG in the home-care
segment.
'China Diabetes Management Devices - Market Trends, Forecast and
Competitive Landscape, 2007 - 2020', a market intelligence report
recently published by ABMRG, covers most diabetes management and
diagnostic devices. It provides historical and statistically
refined forecast data for the segments covered.
It not only puts forth a detailed overview of historical trends
and forecasts (2007-2020), the annualized trends for sales in terms
of value and volume, market growth, pricing (Average Selling Price
or ASP), competitive landscape and market share, but offers a
cross-category comparison, market drivers, market restrains and
challenges. In addition, it presents an inclusive account of global
industry developments for the past two years, including M&As,
partnerships, clinical studies, pipeline, product approvals and
launches, recalls and litigations, market dynamics and market
drivers and restrains.
The key players in this market are Abbott Laboratories (NYSE:
ABT), ARKRAY INC., B. Braun Melsungen AG, Becton, Dickinson and
Company (NYSE: BDX), F. Hoffmann-La Roche Ltd (ROG: SIX), Johnson
& Johnson (NYSE: JNJ), Lifescan, Inc., Medtronic, Inc. (NYSE:
MDT), Novo Nordisk A/S (Copenhagen: NOVOb.CO #Reuters; NYSE: NVO), San
Meditech (Huzhou) Co. Ltd, and Terumo CORPORATION (TSE: 4543).
Why one should buy this report
The report can be instrumental in making strategic decisions
pertaining to:
- Competitive diabetes product launch
- Capital investments based on the forecast for high potential
diabetes segments.
- Capitalization of opportunities in high-growth geographies and
attractive diabetes markets.
- Identifying in-licensing and out-licensing opportunities, and
recognizing potential business partners and M&A targets within
the diabetes market.
- To plan and make capital investments based on the forecast for
high potential diabetes devices segments.
- To prepare management and strategic presentations for the
investors and shareholders.
- This report is an essential source for in-depth information and
data relating to the China
diabetes devices market. It also offers detailed and comprehensive
coverage of market revenue, volume, distribution and company share
information; and latest news, financial
Other strategic market reports:
- Australian Diabetes Management Devices Market, 2007 -
2020
http://www.abmrg.com/Australian-Diabetes-Management-Devices-Market-2007-2020.html
- Asia Pacific Diabetes Management Market Outlook Through
2020
http://abmrg.com/Asia-Pacific-Diabetes-Management-Market-Outlook-Through-2020.html
- Europe Diabetes Management Market Outlook Through
2020
http://abmrg.com/Europe-Diabetes-Management-Market-Outlook-Through-2020.html
About ABMRG
ABMRG (Ace Business and Market Research Group) is a research and
consulting firm focused on life sciences. It offers comprehensive
research and analytical studies targeting various therapeutic
sectors and market dynamics, vital trends, business strategies and
clinical pipeline. Its cutting edge reports empower companies to
make smarter, effective and faster strategic decisions for business
growth.
Contact:
Ankit Jian
sales@abmrg.com
19@abmrg.com
+91-8238155239
+91-261-2216406
SOURCE ABMRG
